Oncolytics Biotech Inc
TSX:ONC

Watchlist Manager
Oncolytics Biotech Inc Logo
Oncolytics Biotech Inc
TSX:ONC
Watchlist
Price: 14.9 CAD -1.32% Market Closed
Market Cap: 173.1m CAD

Relative Value

There is not enough data to reliably calculate the relative value of ONC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ONC Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-0.9
Industry
24
Forward
-5.6
vs History
vs Industry
7
Median 3Y
-0.8
Median 5Y
-1
Industry
21.6
vs History
vs Industry
5
Median 3Y
-0.8
Median 5Y
-1
Industry
23.7
vs History
1
vs Industry
7
Median 3Y
1.2
Median 5Y
1
Industry
3.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
0.2
Median 5Y
0.3
Industry
6.7
Forward
-2.5
vs History
vs Industry
Median 3Y
0.2
Median 5Y
0.3
Industry
7.2
Forward
-3.7
vs History
vs Industry
8
Median 3Y
0.3
Median 5Y
0.4
Industry
8.2
vs History
vs Industry
7
Median 3Y
0.3
Median 5Y
0.3
Industry
6.7
vs History
1
vs Industry
14
Median 3Y
-1.8
Median 5Y
-2.9
Industry
5.7

Multiples Across Competitors

ONC Competitors Multiples
Oncolytics Biotech Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Oncolytics Biotech Inc
TSX:ONC
173.1m CAD 0 -5.7 -5.2 -5.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 924 975 -161 240.4 -195 797.2 -193 563
US
Abbvie Inc
NYSE:ABBV
395.4B USD 6.6 168.4 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
171.5B USD 4.8 24.5 17.8 17.8
US
Gilead Sciences Inc
NASDAQ:GILD
153.5B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.9B USD 9.6 30.7 22.5 23.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 076.6 -529.9 -577 -561.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.6B USD 5.4 17 16.1 18.3
AU
CSL Ltd
ASX:CSL
86.6B AUD 3.7 19.3 13 16.2
NL
argenx SE
XBRU:ARGX
46.7B EUR 15.1 35.6 61.6 63.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.6B USD 16.7 1 230.6 161.8 196.2
P/S Multiple
Revenue Growth P/S to Growth
CA
Oncolytics Biotech Inc
TSX:ONC
Average P/S: 3 392 711.9
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 924 975
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 076.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
15.1
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
46%
0.4
P/E Multiple
Earnings Growth PEG
CA
Oncolytics Biotech Inc
TSX:ONC
Average P/E: 193.1
Negative Multiple: -5.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 240.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.5
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
9%
1.9
AU
CSL Ltd
ASX:CSL
19.3
11%
1.8
NL
argenx SE
XBRU:ARGX
35.6
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 230.6
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Oncolytics Biotech Inc
TSX:ONC
Average EV/EBITDA: 40.2
Negative Multiple: -5.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 797.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.8
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
11%
1.5
AU
CSL Ltd
ASX:CSL
13
8%
1.6
NL
argenx SE
XBRU:ARGX
61.6
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
161.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Oncolytics Biotech Inc
TSX:ONC
Average EV/EBIT: 46.4
Negative Multiple: -5.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 563 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
13%
1.4
AU
CSL Ltd
ASX:CSL
16.2
11%
1.5
NL
argenx SE
XBRU:ARGX
63.3
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
196.2
N/A N/A